Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
OBJECTIVE: To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. STUDY DESIGN: Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. POPULATION: A total of 893 patients with...
প্রধান লেখক: | Fisher, C, Dhainaut, J, Opal, S, Pribble, J, Balk, R, Slotman, G, Iberti, T, Rackow, E, Shapiro, M, Greenman, R |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
1994
|
অনুরূপ উপাদানগুলি
-
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
অনুযায়ী: Fisher, C, অন্যান্য
প্রকাশিত: (1993) -
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
অনুযায়ী: Peter Kirk, অন্যান্য
প্রকাশিত: (2021-05-01) -
Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells
অনুযায়ী: Huan Wang, অন্যান্য
প্রকাশিত: (2021-03-01) -
Effectiveness and economic evaluation of rhTPO and rhIL-11 in the treatment of cancer therapy induced thrombocytopenia based on real-world research
অনুযায়ী: Fa-Min Gong, অন্যান্য
প্রকাশিত: (2024-01-01) -
Cardiorenal Syndromes and Sepsis
অনুযায়ী: C. Chelazzi, অন্যান্য
প্রকাশিত: (2011-01-01)